Maximilian Diehn

Maximilian Diehn (M.D./Ph.D.) is a co-founder of Foresight Diagnostics and Associate Professor of Radiation Oncology, Vice Chair of Research, and Division Chief of Radiation and Cancer Biology at Stanford University. Dr. Diehn has a long track record of research accomplishments in the fields of cancer genomics and cancer biology. His prior work focused on gene expression profiling of solid tumors and treatment resistance. More recently, and in close collaboration with Dr. Alizadeh’s group, his laboratory has developed novel liquid biopsy methods for detection of circulating tumor DNA. Currently, his research is focused on developing and applying liquid biopsy approaches to early detection, minimal residual disease, treatment response monitoring, and analysis of tumor heterogeneity. Clinically Dr. Diehn specializes in the treatment of lung cancer. He also manages a broad clinical research portfolio that includes multiple investigator initiated clinical trials focused on improving personalized therapy for patients with lung cancer, including through the application of liquid biopsies.